CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash
Hagens Berman is soliciting Capricor Therapeutics investors who suffered losses to contact the firm regarding a potential securities class action lawsuit. The firm's investigation centers on whether Capricor misled investors about the efficacy of its lead candidate Deramiocel, citing a reported 64% stock drop following an FDA briefing document.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.